Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
EDITORIAL Cardiovascular Research (2012) 93, 10–11 doi:10.1093/cvr/cvr293 A novel adult human ventricle slice preparation for cardiac drug discovery and safety pharmacology Michael J. Curtis* Cardiovascular Division, King’s College London, Rayne Institute, St Thomas’ Hospital, London SE17EH, UK Online publish-ahead-of-print 2 November 2011 The editorial refers to ‘Organotypic slice culture from human adult ventricular myocardium’ by M. Brandenburger et al., pp. 50–59, this issue. Cardiac drug discovery and cardiac safety pharmacology assessment both require new models/methods to advance strategy.1 – 6 Ventricular arrhythmias are no longer a major focus for therapeutic drug discovery, and to become so again, a range of new preclinical models and a novel experimental strategy will be required for detecting desirable effects on cardiac electrophysiology and rhythm.2,3 In the field of cardiac safety pharmacology, new chemical entities that possess the desired target specificity are entered into high throughput screens (HTS) for safety pharmacology frontloading, including assessment of torsades de pointes liability.4 – 6 An integrated safety assessment strategy has appeared during the past 10 years, and optimization of the deployment of the numerous available constituent methods continues to evolve.4 Part of this involves the search for more inexpensive, more predictive medium-throughput screens that fit somewhere between the crude HTS methods, and the expensive and technically demanding late-stage safety screens.4 – 6 In cardiac safety and discovery, the headline goals are the same: to determine what a drug does to cardiac ion channels and how this manifests as an integrated outcome (i.e. effect on action potential configuration, conduction and refractoriness, rhythm and function).1 – 6 The human ventricular slice preparation described by Brandenburger et al.7 may have a role both in antiarrhythmic drug discovery and in safety assessment going forward. Its potential value arises from several of its aspects. First, it is a human tissue preparation. In research, we justify the use of animals on the basis of the utility of the readout vs. ethical considerations. Readout utility, in drug discovery and safety assessment, means clinical relevance. We can never know the clinical relevance of any method, model, or screen until we have a complete validation data set.3,4 This means a portfolio of evidence that shows that drugs that alter the designated readout of the screen do so in a way that predicts, with precision and accuracy, the effects in humans. For example, if the model is an HTS channel screen, for the screen to be validated we need to know that all drugs that block the channel, and only drugs that block the channel, produce the effect of interest in humans (the effect of interest being a good effect if this is a discovery screen, and an adverse effect if this is a safety screen). Of course, there are few if any screens (for discovery or safety) that fully comply with this requirement for a variety of reasons, the most poignant being that we may not yet have a range of drugs effective in humans (a template) with which to validate the model. This is poignant because models are most needed for diseases that are the most poorly treated and, hence, have the fewest positive control drugs to construct a response template (this is known as the model validation paradox).4 There is no way of ensuring that any new model is valid until it is validated. However, in the absence of proof, the likelihood is improved if the model is a human tissue model, through the process of positive reinforcement.3 The second reason why the new model may have advantages in discovery and safety is that it is a slice preparation rather than a single cell preparation, and it is an adult heart cell preparation. The syncytium is electrophysiologically complete in two dimensions in an organotypic thin-slice culture, but it is absent in the next preparation ‘down’—an isolated adult myocyte—and unavailable in adult form in myocyte/fibroblast cell co-culture. The combination of adult human and syncytium gives potential added value greater than the sum of the parts. The third reason why the new model may have advantages is that the thin slice means that cells remain viable in superfusion culture for long periods,7 allowing for complex experimentation as well as routine investigation. In addition, and connected with this, the preparation may be used for contractile function assessment (by standard one-dimensional analysis) providing a separate readout for viability plus the possibility of simultaneous measurement of drug effects on electrical and mechanical readout in human ventricle.7 The value of the viability is not so much the prospect of allowing for long experiments, but that it allows for harvested heart tissue to be stored for later use. This is extremely important because the availability of (fresh human) tissue is likely to be a critical issue in most research centres. The present study shows that after 28 days storage in culture, 67% of preparations met electrophysiological study entry criteria.7 The hit rate was less (33%) for contractility criteria, and the function readout did run down markedly over 28 days (both the The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology. * Corresponding author. Tel: +44 2071881095; fax: +44 2071883902, Email: [email protected] Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: [email protected]. 11 Editorial inotropic capacity and the lusitropic phenotype, especially relating to elastance),7 but this nevertheless represents value, especially given that b-agonist responses (fold changes in force and EC50) were undiminished even after 28 days.7 The contractile rundown was attributable to remodelling typical in unloaded heart tissue; it was not caused by necrosis.7 Viability validation was substantiated by extensive and detailed histological, biochemical, and other assessments, including ion channel mRNA expression and action potential duration responsiveness to dofetilide and rilmakalim.7 Conservation of the latter drugs’ effects is of particular relevance to readers interested in cardiac safety pharmacology. These are all benefits of the thin-slice preparation and are important in that they represent their first realization in an adult human ventricle. The question that needs to be addressed is whether these potential advantages give rise to more effective translational readout. To be effective, the model needs to be available on demand. This requires a reliable supply of viable human tissue. This potential limitation is certainly obviated to a great extent by the storable properties of the preparation and the associated longevity, but the practicality will need to be fully explored in any centre wishing to use the preparation. Moreover, to have advantage, the model needs to give readout that is more clinically relevant than readout that could have been derived from slices of animal ventricle (dog, or the less expensive and less ethically nuanced guinea pig, for example) or from other human or animal cardiac preparations (isolated hearts, cells, or membrane preparations). It is implicit that if the present model does provide readout that is more clinically relevant than that from other models, the readout must be different in some way. For example, the model must detect an effect of at least one drug or drug class that is missed or is qualitatively or quantitatively different (in a substantial and relevant way) when evaluated in all other models. The real value of the new model therefore requires that it be shown to be different, and that the difference is shown to be uniquely predictive of effects in intact humans. This may seem to be a harsh stricture, but it applies to any new model. It should be considered not only when a human tissue model is proposed, but also when a transgenic mouse or zebrafish model is introduced. The difference, of course, is that inexpensive and/or ethically unchallenging models are used with fewer pauses for thought than human tissue models, and this includes pause for thought about the validity of the readout. All these factors considered should prompt investigators to examine the potential value of the new model7 with an unbiased approach. Aside from the obvious questions that I have raised, and that cannot yet be answered, one may consider whether the longevity of the preparation confers any advantage in addition to the one noted above. In drug screening, one drug will require one preparation, meaning that extended longevity has no real value in that context. Perhaps longevity may allow the study of electrical or mechanical remodelling, but this will require validation (especially with respect to time-matching, a key issue noted by the inventors).7 Does the fact that contractile activity can be measured confer any advantage? It could be argued that we recognize that contractile function is subtle, meaning that its evaluation requires readout that can be obtained only at the whole organ level. Is it possible to measure inotropy and lusitropy in a meaningful way in the slice preparation? If not, the benefit obtained from the mechanical function readout may be limited. However, these are questions for the future. Presently, we have the makings of a valuable new model that will succeed or fail on the strength of evolving validation research. Conflict of interest: none declared. References 1. Anders H-J, Vielhauer V. Identifying and validating novel targets with in vivo disease models: guidelines for study design. Drug Discov Today 2007;12:446 –451. 2. Clements-Jewery H, Andrag E, Curtis MJ. Druggable targets for sudden cardiac death prevention: lessons from the past and strategies for the future. Curr Opin Pharmacol 2009;9:146 –153. 3. Curtis MJ. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 1998;39: 194 –215. 4. Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. Br J Pharmacol 2008;154:1382 –1399. 5. Lee N, Authier S, Pugsley MK, Curtis MJ. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight? Toxicol Appl Pharmacol 2010;243:146 –153. 6. Gintant GA. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008; 119:199 –209. 7. Brandenburger M, Wenzel J, Bogdan R, Richardt D, Nguemo F, Reppel M et al. Organotypic slice culture from human adult ventricular myocardium. Cardiovas Res 2012;93: 50 –59.